Want to see MBAI full AI Analyst Report?
MBAI Stock Chart & Stats
$1.09
-$0.02(-1.80%)
―
--
Day’s Range― - ―
52-Week Range$0.59 - $3.92
Previous CloseN/A
VolumeN/A
Average Volume (3M)57.88K
Market Cap
$7.65M
Enterprise Value$7.97M
Total Cash (Recent Filing)$265.00K
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)1.7
Beta1.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,020,502
10 Day Avg. Volume46,440
30 Day Avg. Volume57,877
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-219.48
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Potential Revenue StreamsThe potential for revenue through product sales, partnerships, and licensing agreements could provide significant growth opportunities, especially as the company seeks regulatory approvals and market expansion.
Innovative Product OfferingThe C-Scan technology represents a novel approach in colorectal cancer screening, potentially offering a competitive advantage in the medical diagnostics industry by providing a patient-friendly, preparation-free option.
Strong Equity PositionA strong equity position with no debt provides financial stability and flexibility, allowing the company to potentially weather financial challenges and invest in growth opportunities without the burden of debt repayments.
Bears Say
Persistent LossesOngoing losses highlight financial instability and the difficulty in achieving profitability, which may limit the company's ability to attract investment and sustain operations without external funding.
Negative Cash FlowsPersistent negative cash flows indicate ongoing operational challenges, which can deplete cash reserves over time and hinder the company's ability to invest in growth or respond to market opportunities.
Lack Of Revenue GenerationThe absence of revenue generation poses a significant risk to the company's long-term sustainability, as it relies on its cash reserves without generating income to support operations and growth.
Check-Cap News
MBAI FAQ
What was Check-Cap Ltd.’s price range in the past 12 months?
Check-Cap Ltd. lowest stock price was $0.59 and its highest was $3.92 in the past 12 months.
What is Check-Cap Ltd.’s market cap?
Check-Cap Ltd.’s market cap is $7.65M.
When is Check-Cap Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Check-Cap Ltd.’s earnings last quarter?
Currently, no data Available
Is Check-Cap Ltd. overvalued?
According to Wall Street analysts Check-Cap Ltd.’s price is currently Undervalued.
Does Check-Cap Ltd. pay dividends?
Check-Cap Ltd. does not currently pay dividends.
What is Check-Cap Ltd.’s EPS estimate?
Check-Cap Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Check-Cap Ltd. have?
Check-Cap Ltd. has 7,020,502 shares outstanding.
What happened to Check-Cap Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Check-Cap Ltd.?
Currently, no hedge funds are holding shares in MBAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Check-Cap Ltd.
Check-Cap Ltd. is a medical diagnostics entity currently in its clinical development phase, dedicated to advancing screening solutions that utilize capsule-based technology. This firm was established in 2004 and conducts its primary operations from Isfiya, Israel.
Ownership Overview
―
Insiders
0.04% Mutual Funds
<0.01% Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---